| 摘要 |
In one embodiment, the present invention provides a stable lyophilized fo rmulation comprising an anti-EGFR antibody, preferably cetuximab; lactobioni c acid; and a buffer, preferably histidine. In one preferred embodiment, the present invention provides a stable lyophilized formulation comprising abou t 50 mg/mL to about 140 mg/mL of ERBITUX?, about 0.125% lactobionic acid, ab out 25 mM histidine buffer at a pH of about 6.0, about 0.005% Tween 80, and about 1.875% glycine.
|
